


UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: June 4, 2026
Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order		5:02 PM EST		
A. Minutes from previous meetings		Review of Minutes from March 5, 2026	Minutes reviewed, approved	Yes
B. Hot Topic		Streamlining Pharmacy Prior Authorization (PA) Programs and Process – UHC Medicaid	Non-voting item	
C. Formulary Review - New Drugs		Ayavase		
Comment		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Cardamyst		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Dr. [REDACTED] inquired about other treatment options available for patients that could have an issue while traveling or on vacation that would require going to an emergency room.		
		[REDACTED] replied, this is a first in class medication, no other medications or devices on the market for this type of use.		
		Diltiazem HCl ER (12h)		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Quinidine Gluc. CR		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Cloxic		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Fluocinolone 0.01% Otic Oil		
		Recommendation: • Preferred across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Hymuo		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Omlont		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Apraclonidine		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Betaxolol HCl		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Phospholine Iodide		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Zycubo		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Myozor		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Redemlo		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Voyzact		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
D. Formulary Review - New Formulations		Confirm Review of New Formulations Grid	Yes/No	Yes
		Recommendation: • Wegovy oral tablet: Non-preferred with prior authorization (MACE)/Benefit Exclusion (Weight Loss) across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Wegovy HD: Benefit Exclusion across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Vybrique: Benefit Exclusion across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
E. Formulary Review - PDL Modifications		Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • Bryns: Move to preferred across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • budesonide/formoterol: Move to preferred across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • tofacitinib/hydrocortisone XR: Move to preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Enbrel/Enbrel Sureclick/Enbrel Mini: Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Insulin lispro KwikPen/insulin lispro Jr KwikPen: Move to Preferred with step therapy (insulin lispro vial, Lantus pens, Rezvoglar pens) across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • FC2: Move to preferred across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • clemastine: Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Ventolin HFA (authorized generic): Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Ventolin HFA (generic): Move to preferred across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Proventil HFA (generic) (additional NDCs): Move to preferred across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Proair HFA (generic) (additional NDC): Move to preferred across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Rulicason Diskus: Move to preferred across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Anoro Ellipta (brand): Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Incuse Ellipta (brand): Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • dapagliflozin (authorized generic): Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • dapagliflozin (generic): Move to preferred across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Seglatro: Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • dapagliflozin/metformin ER: Move to preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Saglunomet: Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Procrit: Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Epogen: Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • metronidazole 0.75% lotion: Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • cefpodoxime suspension: Move to preferred (age maximum of 12) across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • alendronate 70 mg/75 mL: Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Neocurna: Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • Siruro: Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Recommendation: • tadalafil 2.5 mg: Move to non-preferred with prior authorization across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0

Agenda Item	Speaker	Recommendation	Conclusions/ Recommendations	Vote
P. Formulary Review - New Drugs- Medical		Confirm Review of New Drugs- Medical Grid	Yes/No	Yes
		ivinsm Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Exdenu Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Yartemlea Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Camcevi ETM Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Lunsumio Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Lunsumio Velo Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Gammagard Liquid ERC Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
		Qivig Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Mo ion made, seconded, and carried to accept recommendation	7:0
G. Formulary Review - Drugs Evaluated Per Grid		Apply recommendations as outlined in grid	Mo ion made, seconded, and carried to accept recommendation	7:0
H. Clinical Guidelines		Clinical Guideline Review	Yes/No	Yes
		Apply New Pharmacy Guidelines	Mo ion made, seconded, and carried to accept recommendation	7:0
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Mo ion made, seconded, and carried to accept recommendation	7:0
		Remove Pharmacy Guidelines Requiring Archival	Mo ion made, seconded, and carried to accept recommendation	7:0
I. Quality Monitoring		Confirm Review of Quality Data	Yes/No	Yes
		QUR Review - GOUR		
		Drug Recalls – 1st Quarter 2026		
		Top 25 Drugs by Spend and Volume – 1st Quarter 2026		
		Top 10 Drugs Requested – Approvals and Denials – 1st Quarter 2026		
		Grievances and Appeals Data – 1st Quarter 2026		
		Inter-Rater Reliability (IRR) – 1st Quarter 2026		
		Pharmacies		
Adjournment			6:57 PM EST	
Respectfully Submitted to the Committee				
 W. S. T. A. R. Ph. (VP, Medical Pharmacy Strategy)				